Multiply Labs raises a $75M Series B to scale physical-AI robots for gene-therapy and mRNA drug manufacturing

What changed

San Francisco robotics company Multiply Labs disclosed a $75 million Series B on October 6, led by NantWorks with participation from investors including AstraZeneca, Lux Capital and Founders Fund, bringing total funding above $100 million. The company applies robotics and AI to automate complex biomanufacturing workflows for products such as gene therapies and mRNA medicines. Multiply Labs lists collaborations with AstraZeneca, Legend Biotech and Kyverna Therapeutics. The round is intended to scale its physical-AI manufacturing platform rather than launch a consumer AI model.